Marinus Pharmaceuticals Highlights the P-III (RAISE) Study Data of Ganaxolone to Treat Refractory Status Epilepticus (RSE) at NCS 2024
Shots:
- The pivotal P-III (RAISE) study assessed the safety & efficacy of ganaxolone (IV) vs PBO, combine with SoC, to treat refractory status epilepticus in patients who failed at least two antiseizure medications
- Study achieved prespecified 2EPs, showing a median time to SE cessation of 4.2min. vs 307.2min. with 45% vs 19% of them having no treatment escalation within 24hrs.
- Previously reported topline results were also highlighted, showing 80% vs 13% SE cessation within 30min., reduction in EEG seizure burden by 93% vs 36% and patient proportion not progressing to IV anesthesia for 36hrs. following initiation of IV ganaxolone was 63% vs 51% that was not significant
Ref: Marinus | Image: Marinus
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
